Nyxoah מכריזה על אירועי משקיעים קרובים

מונט-סנט-גיברט, בלגיה, 2 בספטמבר 2025, (GLOBE NEWSWIRE) :

Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH) ,חברת טכנולוגיות רפואיות שמתמקדת בפיתוח ומסחור של פתרונות ושירותים חדשניים לדום נשימה בשינה (OSA), הודיעה היום כי החברה תשתתף באירועים הבאים במהלך חודש ספטמבר:

Nyxoah Announces Upcoming Investor Events

Mont-Saint-Guibert, Belgium – September 2, 2025, 10:30pm CET / 4:30PM ET – GLOBE NEWSWIRE:

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the following events during September:

2025 Wells Fargo Healthcare Conference
September 3^rd – Boston, MA

Cantor Global Healthcare Conference 2025
September 4^th – New York, NY
Fireside Chat: 11:30-12:00 pm ET
Webcast: Cantor Fireside Chat Webcast

Morgan Stanley 23^rd Annual Global Healthcare Conference
September 9^th – New York, NY
Presentation Time: 5:35-6:10 pm ET
Webcast: : Morgan Stanley Fireside Chat Webcast

Baird's 2025 Global Healthcare Conference
September 10^th – New York, NY

A live webcast of the events can be accessed by visiting Nyxoah’s Investor Relations website and will be available for replay following the events. The Company will also be available for 1x1 meetings with institutional investors attending the events.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and U.S. FDA approval of a Premarket Approval application.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

For Media
In United States
FINN Partners – Alyssa Paldo
[email protected]

In International/Germany
MC Services – Anne Hennecke
[email protected]

In Belgium/France
Backstage Communication – Gunther De Backer
[email protected]

Attachment

• ENGLISH_Nyxoah Announces UpcomingInvestor Events_FINAL

*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית GlobeNewswire